CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
Masayuki Saruta, Dong Il Park, Young-Ho Kim, Suk-Kyun Yang, Byung-Ik Jang, Jae Hee Cheon, Jong Pil Im, Takanori Kanai, Tatsuro Katsuno, Yoh Ishiguro, Makoto Nagaoka, Naoki Isogawa, Yinhua Li, Anindita Banerjee, Alaa Ahmad, Mina Hassan-Zahraee, Robert Clare, Kenneth J. Gorelick, Fabio Cataldi, Mamoru Watanabe, Toshifumi Hibi
Intest Res. 2020;18(1):45-55.   Published online January 30, 2020
DOI: https://doi.org/10.5217/ir.2019.00039

Excel Download

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
Intestinal Research. 2020;18(1):45-55   Crossref logo
Link1 Link2 Link3

825 Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA Study
Gastroenterology. 2015;148(4):S-162   Crossref logo
Link1 Link2

W1042 Mechanistic Population Pharmacokinetics (PK) Model of PF-00547659, a Fully Human IgG2 Anti-MAdCAM Antibody, in Ulcerative Colitis Patients: Results of a First in Human (Fih) Study
Gastroenterology. 2009;136(5):A-641   Crossref logo
Link1 Link2

Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody
British Journal of Pharmacology. 2009;157(2):281-293   Crossref logo
Link1 Link2

901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study
Gastroenterology. 2015;148(4):S-1193   Crossref logo
Link1 Link2

867 Anti-MAdCAM Monoclonal Antibody PF-00547659 Does Not Affect Immune Surveillance in the Central Nervous System of Crohn's Disease Patients Who Are Anti-TNF Inadequate Responders: Results From the Tosca Study
Gastroenterology. 2014;146(5):S-150   Crossref logo
Link1 Link2

Biological Therapy of Crohn’s Disease: Natalizumab, Vedolizumab, and Anti-MadCAM
Crohn's Disease and Ulcerative Colitis. 2017;375-380   Crossref logo
Link1

P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY
Gastroenterology. 2019;156(3):S26-S27   Crossref logo
Link1 Link2

P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY
Inflammatory Bowel Diseases. 2019;25(Supplement_1):S18-S19   Crossref logo
Link1

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
The Lancet. 2017;390(10090):135-144   Crossref logo
Link1 Link2